Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

Author: Benzinga Newsdesk | February 29, 2024 04:36pm

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

Posted In: BLRX